Candidemia caused by Meyerozyma guilliermondii species complex in patients with cancer: A systematic review of case reports.

IF 2.3 3区医学 Q3 INFECTIOUS DISEASES

Medical mycology Pub Date : 2025-09-30 DOI:10.1093/mmy/myaf087

Jingchen Tang, Liuyang Cai, Haiyang He, Xiaohui Li, Siqin Liang, Li Zhang, Xiaochun Xue, Bin Xu, Weihua Pan

{"title":"Candidemia caused by Meyerozyma guilliermondii species complex in patients with cancer: A systematic review of case reports.","authors":"Jingchen Tang, Liuyang Cai, Haiyang He, Xiaohui Li, Siqin Liang, Li Zhang, Xiaochun Xue, Bin Xu, Weihua Pan","doi":"10.1093/mmy/myaf087","DOIUrl":null,"url":null,"abstract":"<p><p>Meyerozyma guilliermondii represents an opportunistic pathogen complex threatening immunocompromised patients, notably those with cancer, leading to candidemia characterized by increasing incidence and high mortality risk. However, understanding of candidemia in cancer patients is limited. This study aims to elucidate the epidemiological and clinical features of candidemia by the M. guilliermondii species complex (MGSC) in cancer patients, thereby enhancing disease diagnosis and treatment. A systematic review was performed, analyzing cases from 1967 to 2024 documented in PubMed, Scopus, Embase, and Web of Science using specific terms related to M. guilliermondii and cancer. Additionally, two cancer-related invasive candidiasis cases by M. guilliermondii sensu stricto from Jiangxi Cancer Hospital were included. The review identified 282 cases, with 225 specifying tumor types: 114 hematologic malignancies and 111 solid tumors. A significant increase in cases was noted over the last two decades (92.2%). Predominantly, adults were affected, with a male-to-female ratio of 97:53. Among the precisely identified species in recent years, M. guilliermondii sensu stricto was the most recorded species (83.6%), with nine cases of candidemia due to M. caribbica in cancer patients. The overall mortality was 33.0%. Common factors included central venous catheter (CVC) placement (75.8%), prior broad-spectrum antibiotics (68.5%), and parenteral nutrition (46.1%). Timely CVC removal is crucial for cancer patients with prolonged CVC placement to prevent MGSC-related candidemia. Cancer patients with multiple risk factors are highly susceptible to MGSC-caused candidemia, which is increasing in incidence and mortality risk. Prompt antifungal therapy is essential for improving prognosis.</p>","PeriodicalId":18586,"journal":{"name":"Medical mycology","volume":" ","pages":""},"PeriodicalIF":2.3000,"publicationDate":"2025-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medical mycology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/mmy/myaf087","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}

引用次数: 0

Abstract

Meyerozyma guilliermondii represents an opportunistic pathogen complex threatening immunocompromised patients, notably those with cancer, leading to candidemia characterized by increasing incidence and high mortality risk. However, understanding of candidemia in cancer patients is limited. This study aims to elucidate the epidemiological and clinical features of candidemia by the M. guilliermondii species complex (MGSC) in cancer patients, thereby enhancing disease diagnosis and treatment. A systematic review was performed, analyzing cases from 1967 to 2024 documented in PubMed, Scopus, Embase, and Web of Science using specific terms related to M. guilliermondii and cancer. Additionally, two cancer-related invasive candidiasis cases by M. guilliermondii sensu stricto from Jiangxi Cancer Hospital were included. The review identified 282 cases, with 225 specifying tumor types: 114 hematologic malignancies and 111 solid tumors. A significant increase in cases was noted over the last two decades (92.2%). Predominantly, adults were affected, with a male-to-female ratio of 97:53. Among the precisely identified species in recent years, M. guilliermondii sensu stricto was the most recorded species (83.6%), with nine cases of candidemia due to M. caribbica in cancer patients. The overall mortality was 33.0%. Common factors included central venous catheter (CVC) placement (75.8%), prior broad-spectrum antibiotics (68.5%), and parenteral nutrition (46.1%). Timely CVC removal is crucial for cancer patients with prolonged CVC placement to prevent MGSC-related candidemia. Cancer patients with multiple risk factors are highly susceptible to MGSC-caused candidemia, which is increasing in incidence and mortality risk. Prompt antifungal therapy is essential for improving prognosis.

查看原文本刊更多论文

癌症患者中由吉列蒙氏芽胞菌复合体引起的念珠菌病：病例报告的系统回顾。

吉利蒙地芽胞菌是一种机会性病原体复合体，威胁免疫功能低下的患者，特别是癌症患者，导致念珠菌病，其特点是发病率增加和死亡率高。然而，对癌症患者念珠菌的了解有限。本研究旨在阐明恶性肿瘤患者念珠菌病的流行病学和临床特征，从而提高疾病的诊断和治疗水平。系统回顾分析了1967年至2024年在PubMed、Scopus、Embase和Web of Science中记录的病例，使用与M. guilliermondii和癌症相关的特定术语。此外，我们还收集了2例来自江西省肿瘤医院的严格吉利蒙地支原体感染的肿瘤相关侵袭性念珠菌病病例。该综述确定了282例病例，其中225例指定肿瘤类型：114例血液恶性肿瘤和111例实体瘤。在过去二十年中，病例显著增加（92.2%）。受影响的主要是成年人，男女比例为97:53。在近年精确鉴定的种中，记录最多的是严格吉列蒙地螨（83.6%），有9例癌症患者因加勒比蒙地螨感染念珠菌。总死亡率为33.0%。常见因素包括中心静脉导管（CVC）放置（75.8%），既往广谱抗生素（68.5%）和肠外营养（46.1%）。及时去除CVC对于长期放置CVC的癌症患者预防mgsc相关念珠菌血症至关重要。具有多种危险因素的癌症患者极易感染由mgsc引起的念珠菌病，其发病率和死亡风险均在增加。及时抗真菌治疗对改善预后至关重要。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Medical mycology 医学-兽医学

CiteScore

5.70

自引率

3.40%

发文量

632

审稿时长

12 months

期刊介绍： Medical Mycology is a peer-reviewed international journal that focuses on original and innovative basic and applied studies, as well as learned reviews on all aspects of medical, veterinary and environmental mycology as related to disease. The objective is to present the highest quality scientific reports from throughout the world on divergent topics. These topics include the phylogeny of fungal pathogens, epidemiology and public health mycology themes, new approaches in the diagnosis and treatment of mycoses including clinical trials and guidelines, pharmacology and antifungal susceptibilities, changes in taxonomy, description of new or unusual fungi associated with human or animal disease, immunology of fungal infections, vaccinology for prevention of fungal infections, pathogenesis and virulence, and the molecular biology of pathogenic fungi in vitro and in vivo, including genomics, transcriptomics, metabolomics, and proteomics. Case reports are no longer accepted. In addition, studies of natural products showing inhibitory activity against pathogenic fungi are not accepted without chemical characterization and identification of the compounds responsible for the inhibitory activity.